Saturday 17 October 2026
Export QDEL’s income statement to Excel — free account
QuidelOrtho Corporation
QDEL Healthcare Medical Devices
QuidelOrtho Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, down 1.89% from fiscal 2024. In the quarter to June 2026, revenue grew 2.77%, EPS grew 63.9%, free cash flow fell 61.5% and total debt rose 10.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
12.94
0.97
−6.97%
Follow QDEL
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.45 | 0.42 | 0.71 | 0.74 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(10.82) | (33.96) | 14.68 | (44.01) | |
P/B ratio |
0.67 | 0.61 | 1.01 | 0.98 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.48 | 1.38 | 1.62 | 1.68 | |
EV/EBITDA |
11.79 | 22.24 | 19.76 | 17.23 | |
EV/Operating CF |
(69.31) | 555.78 | 41.98 | 123.34 | |
EV/FCF |
(18.73) | (22.95) | (52.95) | (31.64) | |
Quick Ratio |
0.48 | 0.52 | 0.61 | 0.63 | |
Current Ratio |
1.39 | 1.43 | 1.50 | 1.78 | |
Net Debt/EBITDA |
24.69 | 31.41 | 53.69 | 26.43 | |
Debt/Assets |
50.59% | 47.76% | 45.94% | 46.85% | |
Debt/Equity |
1.63 | 1.45 | 1.38 | 1.31 | |
Asset Turnover |
0.44 | 0.44 | 0.45 | 0.44 | |
Operating CF/Net income |
1.19 | 0.36 | (1.01) | 0.06 | |
Capex/Depreciation |
(0.19) | (0.30) | (0.40) | (0.06) | |
Interest Coverage |
(0.40) | (0.62) | (1.30) | (15.29) | |
Research and Development Expense of Revenue |
7.72% | 7.24% | 6.33% | 5.93% | |
Selling, General and Administrative Expense of Revenue |
30.07% | 32.16% | 26.87% | 26.70% | |
Intangible Assets out of Total Assets |
0.47 | 0.45 | 0.44 | 0.46 | |
Share Based Compensation of Revenue |
1.90% | 1.73% | 1.49% | 1.53% | |
Graham Net Nets |
(2.14) | (2.14) | (1.24) | (1.13) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(87.96%) | (108.46%) | (58.33%) | (57.79%) | |
Free Cash Flow Yield |
(17.68%) | (14.26%) | (4.31%) | (7.20%) | |
Revenue per Share |
9.24 | 9.09 | 10.67 | 10.29 | |
Operating CF per Share |
(1.62) | (0.48) | 1.95 | (0.67) | |
Capex per Share |
(0.37) | (0.50) | (0.67) | (0.72) | |
Free Cash Flow per Share |
(1.99) | (0.98) | 1.28 | (1.39) | |
Cash per Share |
1.81 | 2.06 | 2.50 | 1.44 | |
Shareholders Equity per Share |
25.99 | 27.15 | 28.33 | 29.95 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
25.99 | 27.15 | 28.33 | 29.95 | |
Free Cash Flow |
(136.10) | (67.00) | 86.60 | (94.70) | |
Working Capital |
383.20 | 414.60 | 481.20 | 598.80 | |
Capital Expenditures |
(25.50) | (34.00) | (45.30) | (49.20) | |
Net Current Asset Value |
(2,563.80) | (2,400.30) | (2,401.50) | (2,272.00) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.05 | 0.06 | 0.07 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
313.50 | 322.95 | 349.70 | 340.70 | |
Average Payables |
227.65 | 237.20 | 262.70 | 230.45 | |
Average Inventory |
598.80 | 587.35 | 555.65 | 595.40 | |
Average Assets |
6,047.20 | 6,045.15 | 6,096.45 | 6,238.10 | |
Average Common Equity |
2,283.80 | 2,424.30 | 2,452.50 | 2,611.55 |
Columns are period end dates